Showing 211-220 of 1059 results for "".
Eyes Have It: Bloodless Blephs and More
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/eyes-have-it-bloodless-blephs-and-more/18728/Demand for treatments around the eye continue to grow; patients want big results but little downtime. Dr. Niamtu discusses his "bloodless bleph" and other uses for fillers and toxins.Eczema Discovery; Ortho Dermatologics, Revision, Alastin Product Launches
https://practicaldermatology.com/topics/practice-management/dermwiretv-eczema-discovery-ortho-dermatologics-revision-alastin-product-launches/18353/Regeneron revealed that Dupixent generated sales of $120M within the first nine months of launch. Researchers have identified a possible treatment for moderate-to-severe atopic dermatitis: IL-22 blockade. Product launches or updates from Revision Skincare, Alastin Skincare, Ortho Dermatologics, andUpdates from CSF 2017
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-updates-from-csf-2017/18371/Dermatologists and core cosmetic physicians shared new insights and reviewed the developments in clinical and cosmetic dermatology at the ninth annual Cosmetic Surgery Forum in Las Vegas. Matthew Zirwas, MD addressed interest in oral supplements to support skin health. Neurotoxin pioneer Nick Lowe,The Invasion of the Picoseconds
https://practicaldermatology.com/topics/practice-management/the-invasion-of-the-picoseconds/20763/Pico devices are finding their niche, with expanded applications that may make them more attractive for practices.Regression in Primary Melanomas: Histologic Factors and Prognosis
https://practicaldermatology.com/topics/skin-cancer-photoprotection/regression-in-primary-melanomas-histologic-factors-and-prognosis/21367/Regression was once thought to be a negative prognostic factor in primary melanomas, but new findings suggest otherwise.Assessing the Need for Re-Excision in Mild to Moderate Dysplastic Nevi
https://practicaldermatology.com/topics/skin-cancer-photoprotection/assessing-the-need-for-re-excision-in-mild-to-moderate-dysplastic-nevi/21247/Re-excision may not be clinically warranted in a majority of cases.Invasive Melanoma: Incidence, Mortality Continue to Climb
https://practicaldermatology.com/topics/practice-management/invasive-melanoma-incidence-mortality-continue-to-climb/20780/The burden of disease is growing, despite best efforts to combat melanoma.New Products
https://practicaldermatology.com/columns/new-products/new-products/20472/Update: Oral Therapies for the Treatment of BCC
https://practicaldermatology.com/topics/practice-management/update-oral-therapies-for-the-treatment-of-bcc/21132/With the recent FDA approval of a new oral agent, the therapeutic outlook for BCC is both more diverse and promising.Recently Passed Law Clears Way for New Sunscreen Ingredients
https://practicaldermatology.com/topics/skin-cancer-photoprotection/recently-passed-law-clears-way-for-new-sunscreen-ingredients/21232/By forcing the FDA to clear its backlog of sunscreen ingredients pending review, The Sunscreen Innovation Act is a major win for UV protection efforts.